DENTSPLY SIRONA Inc (NASDAQ:XRAY) Receives Average Rating of “Hold” from Analysts

Share on StockTwits

DENTSPLY SIRONA Inc (NASDAQ:XRAY) has been assigned a consensus recommendation of “Hold” from the fifteen brokerages that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, eight have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $57.67.

XRAY has been the topic of a number of recent research reports. Stifel Nicolaus upped their price target on shares of DENTSPLY SIRONA from $61.00 to $63.00 and gave the company a “buy” rating in a research note on Friday, November 8th. Wellington Shields raised shares of DENTSPLY SIRONA from a “hold” rating to a “gradually accumulate” rating in a research note on Friday, August 2nd. BidaskClub raised shares of DENTSPLY SIRONA from a “sell” rating to a “hold” rating in a research note on Saturday, November 9th. Barrington Research reissued a “buy” rating and issued a $63.00 target price on shares of DENTSPLY SIRONA in a research note on Monday, August 5th. Finally, HC Wainwright reissued a “hold” rating and issued a $60.00 target price on shares of DENTSPLY SIRONA in a research note on Friday.

DENTSPLY SIRONA stock opened at $56.63 on Friday. The company has a market cap of $12.49 billion, a price-to-earnings ratio of 28.17, a PEG ratio of 1.97 and a beta of 0.96. The firm’s fifty day moving average is $54.47 and its 200 day moving average is $54.39. The company has a quick ratio of 1.39, a current ratio of 2.08 and a debt-to-equity ratio of 0.30. DENTSPLY SIRONA has a 52-week low of $34.93 and a 52-week high of $60.15.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $0.57 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.50 by $0.07. The company had revenue of $962.10 million for the quarter, compared to the consensus estimate of $940.38 million. DENTSPLY SIRONA had a net margin of 4.08% and a return on equity of 10.08%. DENTSPLY SIRONA’s revenue was up 3.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.38 earnings per share. On average, equities research analysts anticipate that DENTSPLY SIRONA will post 2.46 earnings per share for the current fiscal year.

In other news, Director Michael C. Alfano sold 10,665 shares of the stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $56.27, for a total value of $600,119.55. Following the sale, the director now owns 15,153 shares of the company’s stock, valued at $852,659.31. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 0.62% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of XRAY. Vanguard Group Inc. grew its holdings in shares of DENTSPLY SIRONA by 7.0% in the second quarter. Vanguard Group Inc. now owns 25,969,056 shares of the medical instruments supplier’s stock worth $1,515,556,000 after purchasing an additional 1,688,546 shares during the last quarter. Nuveen Asset Management LLC bought a new position in shares of DENTSPLY SIRONA in the second quarter worth about $64,278,000. Eagle Asset Management Inc. grew its holdings in shares of DENTSPLY SIRONA by 2,650.9% in the second quarter. Eagle Asset Management Inc. now owns 952,733 shares of the medical instruments supplier’s stock worth $55,601,000 after purchasing an additional 918,100 shares during the last quarter. Parnassus Investments CA grew its holdings in shares of DENTSPLY SIRONA by 54.8% in the third quarter. Parnassus Investments CA now owns 2,403,989 shares of the medical instruments supplier’s stock worth $128,157,000 after purchasing an additional 850,850 shares during the last quarter. Finally, Robeco Institutional Asset Management B.V. grew its holdings in shares of DENTSPLY SIRONA by 1,307.0% in the second quarter. Robeco Institutional Asset Management B.V. now owns 886,027 shares of the medical instruments supplier’s stock worth $51,713,000 after purchasing an additional 823,052 shares during the last quarter. Hedge funds and other institutional investors own 92.93% of the company’s stock.

DENTSPLY SIRONA Company Profile

DENTSPLY SIRONA Inc designs, develops, manufactures, and markets various dental and oral health products, and other consumable healthcare products primarily for the professional dental market worldwide. The company operates in two segments, Technologies & Equipment; and Consumables. Its dental supplies include endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression materials, restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprise dental hand pieces, intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers.

Read More: Outstanding Shares and The Effect on Share Price

Analyst Recommendations for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Analysts Set $33.00 Target Price for SpringWorks Therapeutics
Analysts Set $33.00 Target Price for SpringWorks Therapeutics
Ardelyx Inc  Given Consensus Rating of “Hold” by Analysts
Ardelyx Inc Given Consensus Rating of “Hold” by Analysts
Western Midstream Partners LP  Receives $32.25 Consensus Price Target from Analysts
Western Midstream Partners LP Receives $32.25 Consensus Price Target from Analysts
SL Green Realty Corp  Receives $93.85 Average Price Target from Brokerages
SL Green Realty Corp Receives $93.85 Average Price Target from Brokerages
HC Wainwright Reaffirms Buy Rating for Y-mAbs Therapeutics
HC Wainwright Reaffirms Buy Rating for Y-mAbs Therapeutics
Analysts Set SS&C Technologies Holdings, Inc.  Price Target at $65.91
Analysts Set SS&C Technologies Holdings, Inc. Price Target at $65.91


© 2006-2019 Ticker Report